NatWest Group’s Teva Pharmaceuticals TEVA Stock Holding History

NatWest Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-35,622	Closed	-$2.01M	–	309
2015 Q3	$2.01M	Buy	35,622 +3,552	+11%	+$230K	0.05%	147
2015 Q2	$1.9M	Sell	32,070 -4,107	-11%	-$253K	0.02%	152
2015 Q1	$2.25M	Sell	36,177 -971	-3%	-$56.5K	0.03%	164
2014 Q4	$2.14K	Sell	37,148 -2,831	-7%	-$158K	0.02%	164
2014 Q3	$2.15K	Sell	39,979 -4,038	-9%	-$214K	0.02%	184
2014 Q2	$2.31M	Buy	+44,017	New	+$2.25M	0.1%	174

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

NatWest Group's TEVA Position: Q4 2015 in Review

NatWest Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 35,622 shares — an estimated $2.01M sold.

NatWest Group first reported a position in TEVA in Q2 2014 and held it in 6 quarters. The position peaked at $2.31M in Q2 2014. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

NatWest Group reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 35,622 Teva Pharmaceuticals shares in Q4 2015, an estimated $2.01M.
NatWest Group first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 6 quarters.
NatWest Group's Teva Pharmaceuticals position peaked at $2.31M in Q2 2014.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.